Overview of Dr. Tarhini

Dr. Ahmad Tarhini is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Kaunas Medical Institute and has been in practice 23 years. Dr. Tarhini accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

• UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2003 - 2006

• UPMC Medical EducationResidency, Internal Medicine, 2000 - 2003

• Kaunas Medical InstituteClass of 1999

Certifications & Licensure

• FL State Medical License 2019 - 2025

• GA State Medical License 2018 - 2020

• OH State Medical License 2017 - 2019

• PA State Medical License 2001 - 2018

Clinical Trials

Publications & Presentations

PubMed

• Comparing the rate of immunotherapy treatment change due to toxicity by sex.

  Chua, K., Liu, H., Schneider, B., Sterling, J., Singer, E., Kronstedt, S., Kaldany, A., Srivastava, A., Tarhini, A., Gatti-Mays, M., Gaughan, E., Hu-Lieskovan, S., Alj...> ;Cancer Reports. 2024 Jan 8

• The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhib...

  Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P Ikeguchi, Igor Puzanov, Susanne Arnold, Mi...> ;Cancers. 2023 Oct 10

• Translation of AI into oncology clinical practice.

  Issam El Naqa, Aleksandra Karolak, Yi Luo, Les Folio, Ahmad A Tarhini, Dana Rollison, Katia Parodi> ;Oncogene. 2023 Oct 1
• Join now to see all

Journal Articles

• Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma  

  Igor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  

  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

Lectures

• United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. 

  2019 ASCO Annual Meeting - 6/1/2019

• Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients. 

  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

• Association of Community Cancer Centers(ACCC) 30th National Conference 

  Association of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
• Join now to see all

Authored Content

• Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

• Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

Press Mentions

• Covid-19 Two Years on: Persistent Symptoms of Clinical Trial Disruption Trouble Certain Therapy AreasMarch 31st, 2022

• The Opdualag Effect: Designing First-Line Melanoma Clinical Trials After Anti-LAG-3 Antibody ApprovalMarch 23rd, 2022

• Advanced Melanoma Survival and Costs Differ in Treatment Combo and Sequence ComparisonJune 4th, 2018

• Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  BCBS Blue Card PPO
  BCBS Texas BlueChoice
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Coventry Oklahoma
  First Choice
  First Health PPO
  Great West PPO
  

  Health Net Oregon PPO
  HealthAmerica HealthAssurance PPO
  Highmark BCBS ClassicBlue
  Highmark BCBS PPOBlue
  Humana ChoiceCare Network PPO
  Multiplan PHCS PPO
  Multiplan PPO
  ODS Network
  Providence Health System Personal Option
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment